Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.38 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.38 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | NEK4 | P51957 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879083 | 0.91 | FLT3 (0.47) | BTKMAP4K2FLT3RETBCR | |
| SCHEMBL878980 | 0.88 | CLK4 (0.37) | MAP4K2FLT3RETBCRFGFR1 | |
| SCHEMBL10290356 | 0.86 | KDR (0.40) | MAP4K2FLT3RETBCRFGFR1 | |
| SCHEMBL879122 | 0.84 | MCHR1 (0.41) | BTKKCNH2 | |
| SCHEMBL878930 | 0.82 | FGFR1 (0.48) | BTKMAP4K2FLT3RETBCR | |
| SCHEMBL878946 | 0.82 | RET (0.41) | MAP4K2FLT3RETBCRFGFR1 | |
| SCHEMBL328104 | 0.80 | FLT3 (0.51) | BTKMAP4K2FLT3RETBCR | |
| SCHEMBL878949 | 0.78 | FGFR1 (0.47) | BTKMAP4K2FLT3RETBCR | |
| SCHEMBL878947 | 0.77 | KDR (0.41) | MAP4K2FLT3RETBCRFGFR1 | |
| SCHEMBL879093 | 0.77 | KDR (0.43) | FLT3KDRRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | BTK 4107/4885MAP4K2 309/4885FLT3 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.